Advertisement
Research Article| Volume 17, ISSUE 4, P587-601, July 1995

Safety profile of over-the-counter naproxen sodium

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      The safety of naproxen sodium for over-the-counter use was evaluated based on 48 randomized, double-blind, placebo-controlled clinical trials that evaluated naproxen/naproxen sodium (NAP) for indications appropriate to, and under conditions common to, nonprescription analgesics. Of the 48 studies, 27 were single-dose studies and 21 were multiple-dose studies of 1 to 10 days' duration; 19 studies included ibuprofen and 9 included acetaminophen. A total of 4138 patients received naproxen or naproxen sodium (3589 patients received naproxen 187.5 to 400 mg and 549 received naproxen sodium 220 to 440 mg), 2423 received placebo, 1574 received ibuprofen (200 or 400 mg), and 671 received acetaminophen (500 to 1000 mg). Adverse-event rates were examined in three sets of comparisons: NAP versus placebo (48 studies); NAP versus ibuprofen and placebo (19 studies); and NAP versus acetaminophen and placebo (9 studies). Across all 48 studies, 83% of both the NAP- and placebo-treated patients reported no adverse events. The incidence rates were similar between NAP and placebo, with headache (4.8% NAP, 6.4% placebo), nausea (3.4% NAP, 3.1% placebo), and somnolence (2.7% NAP, 1.9% placebo) the most commonly reported events. Rates of adverse events with NAP, ibuprofen, and acetaminophen were similar.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Data on file, Syntex Laboratories, Inc., Palo Alto, California, 1994.

      2. Syntex Study Report CL 5017.
        A Pharmacokinetic Comparison of Capsule and Tablet Formulations of Naproxen 200 mg and Naproxen Sodium 220 mg. ICM/NAPt1675/USA, Palo Alto, Calif1989
        • MRCA Information Services
        Health Care Remedies Usage Study (July 1992–June 1993). Market Research Corporation of America, Northbrook, Il1994
        • Todd PA
        • Clissold SP
        Naproxen—a reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states.
        Drugs. 1990; 40: 91-137
        • US Food and Drug Administration
        2d ed. ‘COSTART’: Coding Symbols for Thesaurus of Adverse Reaction Terms. Center for Drugs and Biologics, Division of Drug and Biological Products Experience, Rockville, Md1985 (Publication no. HFN-35)
        • Agresti A
        Categorical Data Analysis. John Wiley & Sons, New York1990: 230-235
        • Cochran WG
        Some methods for strengthening the common χ2 tests.
        Biometrics. 1954; 10: 417-451
        • Mantel N
        • Haenszel W
        Statistical aspects of the analysis of data from retrospective studies of disease.
        J Natl Cancer Inst. 1959; 22: 719-748
        • Landis RJ
        • Heyman ER
        • Koch GG
        Average partial association in three-way contingency tables: A review and discussion of alternative tests.
        Int Stat Rev. 1978; 46: 237-254
        • Breslow NE
        • Day NE
        Statistical Methods in Cancer Research, The Analysis of Case-Control Studies. 1. International Agency for Research on Cancer, Lyon1980: 142-146
        • Cooper SA
        Models for clinical assessment of oral analgesics.
        Am J Med. 1983; 75 (Suppl): 24-29
        • US Food and Drug Administration
        Guideline for the Clinical Evaluation of Analgesic Drugs. Center for Drug Evaluation and Research, Group for Analgesic Drugs, Rockville, Md1992
        • Kalbfleisch JD
        • Prentice RL
        The Statistical Analysis of Failure Time Data. John Wiley & Sons, New York1980: 16-19
      3. Data on file, Adverse Drug Reactions Advisory Committee, Woden, ACT, Australia, 1994.

        • Fredell EW
        • Strand LJ
        Naproxen overdose.
        JAMA. 1977; 238 (Letter): 938
      4. Anaprox®/Anaprox® DS.
        in: 48th ed. Physicians' Desk Reference®. Medical Economics Data Production Company, Montvale, NJ1994: 2350-2352
        • Alun-Jones E
        • Williams J
        Hyponatremia and fluid retention in a neonate associated with maternal naproxen overdosage.
        Clin Toxicol. 1986; 24: 257-260
        • Waugh PK
        • Keating DW
        Hypoprothrombinemia in naproxen overdose.
        Drug Intelligence and Clin Pharm. 1983; 17: 549-550
        • Court H
        • Volans GN
        Poisoning after overdose with non-steroidal anti-inflammatory drugs.
        Adv Drug React Acute Poison Rev. 1984; 3: 1-21
        • Martinez R
        • Smith DW
        • Frankel LR
        Severe metabolic acidosis after acute naproxen sodium ingestion.
        Ann Emerg Med. 1989; 8: 1102-1104
        • Litovitz TL
        • Schmitz BF
        • Holm KC
        1988 annual report of the American Association of Poison Control Centers National Data Collection System.
        Am J Emerg Med. 1989; 7: 495-545
        • Litovitz TL
        • Schmitz BF
        • Bailey KM
        1989 annual report of the American Association of Poison Control Centers National Data Collection System.
        Am J Emerg Med. 1990; 8: 394-442
        • Litovitz TL
        • Bailey KM
        • Schmitz BF
        • et al.
        1990 annual report of the American Association of Poison Control Centers National Data Collection System.
        Am J Emerg Med. 1991; 9: 461-509
        • Litovitz TL
        • Holm KC
        • Bailey KM
        • Schmitz BF
        1991 annual report of the American Association of Poison Control Centers National Data Collection System.
        Am J Emerg Med. 1992; 10: 452-505
        • Litovitz TL
        • Holm KC
        • Clancy C
        • et al.
        1992 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System.
        Am J Emerg Med. 1993; 11: 494-555
        • Litovitz TL
        • Clark LR
        • Soloway RA
        1993 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System.
        Am J Emerg Med. 1994; 12: 546-584